Female patients with early non-metastatic breast cancer who received the drug paclitaxel and underwent standard chemotherapy showed improved disease-free survival in a late-stage trial, Spanish scientists reported. Though the study also found a trend toward enhanced overall survival, it failed to achieve statistical significance. Such a benefit "may become evident with a more protracted follow-up," a study author said.

Related Summaries